Evidence map›Paper›PMID 36364957›Full record

ReviewNutrients2022

Indolepropionic Acid, a Gut Bacteria-Produced Tryptophan Metabolite and the Risk of Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease.

Ratika Sehgal, Vanessa D de Mello, Ville Männistö, Jaana Lindström, Jaakko Tuomilehto, Jussi Pihlajamäki, Matti Uusitupa

Open access · goldAbstract readReview
In one paragraph

Review in Nutrients, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 2 pooled it
6.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 62 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Comprehensive SNP-based evaluation of fat mass and obesity-associated geneJournal of diabetes and metabolic disorders · 2025
    Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Nutrients · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Ratika SehgalInstitute of Public Health and Clinical Nutrition, Department of Clinical Nutrition, University of Eastern Finland, 70211 Kuopio, Finland.
Vanessa D de MelloInstitute of Public Health and Clinical Nutrition, Department of Clinical Nutrition, University of Eastern Finland, 70211 Kuopio, Finland.
Ville MännistöDepartment of Medicine, University of Eastern Finland, Kuopio University Hospital, 70211 Kuopio, Finland.
Jaana LindströmPublic Health Prevention Unit, Finnish Institute for Health and Welfare, 00271 Helsinki, Finland.ORCID 0000-0001-9255-020X
Jaakko TuomilehtoPublic Health Prevention Unit, Finnish Institute for Health and Welfare, 00271 Helsinki, Finland.
Jussi PihlajamäkiInstitute of Public Health and Clinical Nutrition, Department of Clinical Nutrition, University of Eastern Finland, 70211 Kuopio, Finland.ORCID 0000-0002-6241-6859
Matti UusitupaInstitute of Public Health and Clinical Nutrition, Department of Clinical Nutrition, University of Eastern Finland, 70211 Kuopio, Finland.ORCID 0000-0001-6052-2001
University of Eastern Finland · FIFinnish Institute for Health and Welfare · FIUniversity of Helsinki · FI

Funding

Horizon 2020 Framework Programme of the European Union 740264
6 · The paper itself

Abstract

An intricate relationship between gut microbiota, diet, and the human body has recently been extensively investigated. Gut microbiota and gut-derived metabolites, especially, tryptophan derivatives, modulate metabolic and immune functions in health and disease. One of the tryptophan derivatives, indolepropionic acid (IPA), is increasingly being studied as a marker for the onset and development of metabolic disorders, including type 2 diabetes (T2D) and non-alcoholic fatty liver disease (NAFLD). The IPA levels heavily depend on the diet, particularly dietary fiber, and show huge variations among individuals. We suggest that these variations could partially be explained using genetic variants known to be associated with specific diseases such as T2D. In this narrative review, we elaborate on the beneficial effects of IPA in the mitigation of T2D and NAFLD, and further study the putative interactions between IPA and well-known genetic variants (

Indexed as

Diabetes Mellitus, Type 2Non-alcoholic Fatty Liver DiseaseAlpha-Ketoglutarate-Dependent Dioxygenase FTOBacteriaHumansIndolesLiverTryptophanAlpha-Ketoglutarate-Dependent Dioxygenase FTOFTO protein, humanindolepropionic acidIndolesTryptophandietgut microbiotaindolepropionic acidinsulinNAFLDtype 2 diabetes

Identifiers

PMID36364957
PMCPMC9653718
OpenAlexW4308325238

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.